Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asparaginase + etoposide + high-dose methotrexate + PD-1 antibody in advanced extranodal NK/T cell lymphoma
ChiCTR2100051208Phase 2Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase, etoposide, methotrexate and PD-1 Monoclonal Antibody in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoints: Progression-Free Survival and Response Rate. Started Oct 2021; status: recruiting.
02
Drugs
pegaspargaseetoposidemethotrexatePD-1 Monoclonal Antibody
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR2100051208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051208.